市场调查报告书
商品编码
1466362
基于风险的监控软体市场:按功能、型态和最终用户划分 - 2024-2030 年全球预测Risk-based Monitoring Software Market by Function (Centralized Monitoring, Reduced Monitoring, Remote Monitoring), Delivery Mode (Cloud-Based, Licensed Enterprise, Web-Based), End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
基于风险的监控软体市场规模预计到2023年为4.0938亿美元,到2024年达到4.5294亿美元,预计到2030年将达到8.4513亿美元,复合年增长率为10.91%。
基于风险的监测 (RBM) 软体为临床团队提供了一个单一平台,可将大量试验资料流转化为可操作的分析。 RBM 软体提高了临床试验和项目的品质和合规性。以风险为基础的监控软体将临床实验地点的资料输入仪表板,并提醒申办者需要进一步调查的情况。由于临床试验数量的增加以及世界各国政府对药物发现和开发的财政支持的增加,RBM 软体的使用正在扩大。然而,实施和安装 RBM 软体的高昂成本可能会限制製药和生物製药公司的采用。此外,RBM 软体的进步提高了软体营运效率,增加了临床试验流程的外包,预计将增加製药公司对 RBM 软体的采用。
主要市场统计 | |
---|---|
基准年[2023] | 40938万美元 |
预测年份 [2024] | 4.5294亿美元 |
预测年份 [2030] | 84513万美元 |
复合年增长率(%) | 10.91% |
用于功能性远端监控活动的基于风险的监控软体的出现
集中监控是指从一个中心位置对临床试验资料和流程进行系统监控。集中监控对于提高资料品质和确保试验完整性至关重要,而无需进行现场存取。减少监测是指最大限度地减少传统的现场监测访问和活动,转而关注直接影响临床试验品质和病人安全的关键资料和流程。远端监控允许CRA(临床研究助理)审查临床试验资料,利用电子手段与临床试验地点进行通信,并在异地进行监控活动。触发监控是一种自适应方法,可根据透过资料分析确定的特定触发或风险指标来加强工作。
交付模式:云端基础的风险监控软体交付的进展
云端基础的RBM 软体透过网际网路交付并储存在供应商的伺服器上。云端基础的RBM 模式具有高度的弹性、扩充性和成本效率,特别适合中小型企业 (SME) 和IT基础设施有限的组织。获得许可的企业 RBM 软体安装并託管在您自己的伺服器上。获得许可的企业 RBM 软体交付模式是寻求对其软体和资料进行完全控制的大型组织的首选。获得许可的企业 RBM 软体可以进行客製化并与现有系统集成,使其适合具有复杂监控需求和广泛 IT 支援的组织。基于Web的RBM软体可以透过网页浏览器访问,无需安装任何软体。这种类型的交付对于寻求轻鬆存取和使用、最少的 IT 参与和快速部署的组织特别有利。
区域洞察
基于风险的监控 (RBM) 软体的使用在美洲和欧洲不断增加。随着亚太地区增加对药物发现流程的投资并迅速增加临床试验以确定药物功效和安全性,高效的资料分析和管理解决方案(例如基于风险的监控软体)的需求不断增长此外,製药公司和研究机构正在从委外研发机构(CRO) 外包临床前服务,以支援具有成本效益的药物开发。此外,临床研究机构正在全部区域迅速扩张,为 RBM 软体部署创造了巨大潜力。 2022年8月,一个新的研究机构—卡明全球流行病治疗中心在澳洲成立,旨在开发药物来治疗可能引起全球大流行的病原体引起的疾病。此外,基于风险的软体的技术进步和改进,以创建可操作的资料集来支援临床专案和研究,预计将推动全球製药公司和 CRO 的采用。
FPNV定位矩阵
FPNV 定位矩阵对于评估基于风险的监控软体市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对基于风险的监控软体市场中供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.基于风险的监控软体市场的市场规模和预测是多少?
2.在基于风险的监控软体市场的预测期内,有哪些产品、细分市场、应用程式和领域需要考虑投资?
3.基于风险的监控软体市场的技术趋势和法规结构是什么?
4.基于风险的监控软体市场主要供应商的市场占有率是多少?
5. 进入风险监控软体市场的合适型态和策略手段是什么?
[196 Pages Report] The Risk-based Monitoring Software Market size was estimated at USD 409.38 million in 2023 and expected to reach USD 452.94 million in 2024, at a CAGR 10.91% to reach USD 845.13 million by 2030.
Risk-based monitoring (RBM) software provides clinical teams with a single platform that transforms numerous study data streams into actionable analytics. RBM software improves the quality and compliance of a clinical trial or program. A risk-based monitoring software feeds data from study sites into a dashboard, which then alerts the sponsor to situations that need further investigation. The increase in the number of clinical trials and financial support from governments worldwide for drug discovery and development is expanding the use of RBM software. However, the high cost of implementation and installation of RBM software may limit their adoption by pharmaceutical and biopharmaceutical companies. Moreover, advancements in RBM software to improve the operational efficiency of the software and growing outsourcing of clinical trial processes are expected to increase the deployment of RBM software across pharmaceutical companies.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 409.38 million |
Estimated Year [2024] | USD 452.94 million |
Forecast Year [2030] | USD 845.13 million |
CAGR (%) | 10.91% |
Function: Emergence of risk-based monitoring softwares for remote monitoring activities
Centralized monitoring entails systematically monitoring clinical trial data and processes from a central location. Centralized monitoring is crucial for enhancing data quality and ensuring trial integrity without the necessity of on-site visits. Reduced monitoring refers to minimizing traditional on-site monitoring visits and activities, focusing instead on critical data and processes that directly impact trial quality and patient safety. Remote monitoring allows CRAs (Clinical Research Associates) to perform their monitoring activities off-site, utilizing electronic means to review trial data and communicate with trial sites. Triggered monitoring is an adaptive approach where efforts are intensified based on specific triggers or indicators of risk identified through data analytics.
Delivery Mode: Advancements in cloud-based delivery of risk-based monitoring softwares
Cloud-based RBM software is delivered over the internet and stored on the provider's servers. The cloud-based RBM model offers high flexibility, scalability, and cost efficiency, making it particularly suitable for small to medium-sized enterprises (SMEs) or organizations with limited IT infrastructure. Licensed enterprise RBM software is installed and hosted on the customer's own servers. Licensed enterprise RBM software delivery mode is preferred by large organizations seeking full control over their software and data. Licensed enterprise RBM software allows for extensive customization and integration with existing systems, suiting organizations with complex monitoring needs and substantial IT support. Web-based RBM software is accessible through a web browser without software installations. This type of delivery is particularly advantageous for organizations seeking ease of access and use, minimal IT involvement, and fast deployment.
Regional Insights
The utilization of risk-based monitoring (RBM) software is increasing in the Americas, and Europe, attributed to the highly developed pharmaceutical sector in the region. The growing investments in the APAC region for the drug discovery process and surge in clinical trials to determine the effectiveness and safety of drugs are raising the need for efficient data analyzing and management solutions such as risk-based monitoring software. Additionally, pharmaceutical companies and research institutions are outsourcing preclinical services from contract research organizations (CROs) to aid the cost-effective development of drugs. Moreover, the rapid expansion of clinical research institutes across the APAC region is creating significant potential for the deployment of RBM software. In August 2022, a new research institute, the Cumming Global Centre for Pandemic Therapeutics, was established in Australia to develop drugs to treat diseases caused by pathogens that could cause global pandemics. Moreover, the technological advancements and improvements in risk-based software for creating actionable datasets to support clinical programs and research are expected to encourage their adoption by pharmaceutical companies and CROs worldwide.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Risk-based Monitoring Software Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Risk-based Monitoring Software Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Risk-based Monitoring Software Market, highlighting leading vendors and their innovative profiles. These include Anju Software, Inc., ArisGlobal LLC, CGI Inc., Change Healthcare LLC, Clario, CluePoints S.A., Dassault Systemes S.E., DATATRAK International, Inc., DSG, Inc., eClinical Solutions LLC, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA Inc., JMP Statistical Discovery LLC, Laboratory Corporation of America Holdings, LexisNexis Risk Solutions Group, MasterControl Solutions Inc., Mednet, Microsoft Corporation, Octalsoft by Glorant, LLC, Oracle Corporation, Parexel International Corporation, Quanticate International Limited, Scrut Automation, Securitas AB, Signant Health, Sphera Solutions, Inc., TATA Consultancy Services Limited, Veeva Systems Inc., and Wipro Limited.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Risk-based Monitoring Software Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Risk-based Monitoring Software Market?
3. What are the technology trends and regulatory frameworks in the Risk-based Monitoring Software Market?
4. What is the market share of the leading vendors in the Risk-based Monitoring Software Market?
5. Which modes and strategic moves are suitable for entering the Risk-based Monitoring Software Market?